Ask Bock

Dr. Ask Bock

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
ANAsta Maria Blom Nielsen
Asta Maria Blom Nielsen
KNKristiana Alexandrova Nikolova
Kristiana Alexandrova Nikolova
TSTea Sanders Sanders
Tea Sanders Sanders
ABAsk Bock
Ask Bock
MSMoises Alberto Suarez-Zdunek
Moises Alberto Suarez-Zdunek
SNSusanne Dam Nielsen
Susanne Dam Nielsen
Prior to the introduction of antiretroviral therapy (ART), people with HIV (PWH) had high risk of fungemia. No systematic review has assessed the prevalence of fungemia in PWH after the introduction of combination ART in 1996. The primary objective of this systematic review was to determine the prevalence of fungemia in adult PWH after 1996. Furthermore, we aimed to compare the prevalence of fungemia in different ART time periods to determine geographic differences and fungal pathogen distribution. A systematic literature search was performed on 7 March 2025 across six databases and the study quality was assessed using the Newcastle–Ottawa scale. Prevalence estimates were extracted, and a meta-analysis was performed using a random effects model. Twelve studies comprising 27,729 PWH were included. The overall pooled prevalence in PWH was 3.3% (95% CI: 1.53; 4.96%, I2 = 98.9%). The most common pathogen to cause fungemia was Talaromyces marneffei with a prevalence of 4.8%, although this pathogen was limited to studies from Asia. The highest prevalence of fungemia in PWH was 6.8% in Asia. The prevalence of fungemia was 5.8% between July 1996–September 2015 and 1.0% between September 2015–January 2025, but the difference was not statistically significant (p = 0.273). However, all findings were limited by very low certainty of evidence and should be interpreted with caution. In conclusion, our findings suggest that fungemia persists among PWH despite ART, especially in Asia. Given the limited available evidence, it was not possible to determine whether the prevalence of fungemia changed following the change in ART treatment guidelines in September 2015. The protocol is registered in PROSPERO (CRD420251005081).

11 March 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
THThomas Repstorff Holtveg
Thomas Repstorff Holtveg
AJAnne Marie Reimer Jensen
Anne Marie Reimer Jensen
ABAsk Bock
Ask Bock
MSMoises Alberto Suarez-Zdunek
Moises Alberto Suarez-Zdunek
KDKnudsen Andreas Dehlbæk
Knudsen Andreas Dehlbæk
SNSusanne Dam Nielsen
Susanne Dam Nielsen
People with HIV (PWH) have a high risk of peripheral artery disease (PAD), and high-sensitivity troponin (hsTnT) and NT-pro B-type natriuretic peptide (NT-proBNP) may be useful biomarkers for PAD in PWH. We assessed associations between hsTnT and NT-proBNP and both prevalent PAD and de novo PAD. Adult PWH were examined at baseline and after 2 years. Inclusion criteria were (1) measurements of hsTnT and NT-proBNP at baseline and (2) ankle brachial index (ABI) at baseline for prevalent PAD and both visits for de novo PAD. PAD was defined as ABI ≤ 0.9. We included 1011 PWH, and 88 (8.7%) had PAD at baseline. Among 802 PWH, 29 (3.6%) had de novo PAD at follow-up. A doubling in hsTnT concentration was associated with prevalent PAD with an OR 1.41 (95% CI: 1.02–1.96, p = 0.04) and 1.40 (95% CI: 0.99–1.98, p = 0.055) in a base model and an adjusted model, respectively. High hsTnT was associated with a risk ratio of 3.39 (95% CI: 1.24–9.27, p = 0.02) for de novo PAD in an unadjusted model and 3.44 (95% CI: 0.98–12.10, p = 0.05) after adjustments. NT-proBNP was not associated with PAD. Thus, hsTnT was associated with higher odds of prevalent PAD and increased risk of de novo PAD.